Global expansion Frontage has expanded from its New Jersey roots to operate 28 facilities across multiple US states, Canada, Italy, and China, signaling ongoing capacity growth and a broad geographic reach to support multinational CRO/CDMO collaborations.

Acquisition momentum The March 2026 Teddy Lab acquisition in Shanghai demonstrates aggressive growth through strategic M&A, opening opportunities to cross-sell comprehensive lab services and integrated clinical development offerings in China and APAC.

Leadership depth Recent high‑level appointments including Senior Vice Presidents in Clinical Services and Bioanalytical Services, plus senior advisory roles, indicate a strengthened leadership team poised to scale services across early to late stage development and engage larger pharma/biotech clients.

Full‑spectrum capabilities With offerings spanning drug discovery, DMPK, toxicology, formulation development and manufacturing, analytical, clinical trials, bioanalytical, and central labs, Frontage can position as a one‑stop partner for sponsors seeking integrated development pathways.

Financial and scale signals Revenue sits in the mid‑hundreds of millions with substantial funding and a sizable workforce, suggesting the ability to take on larger projects and multimodal programs while competing with mid‑to‑large CROs for global trials.